ETON PHARMACEUTCIALS INC (ETON) competitors & alternatives
Health Care · NASDAQ
ETON PHARMACEUTCIALS INC (ETON)'s top competitors and alternatives — its most similar public companies — include BioMarin Pharmaceutical (BMRN), Jazz Pharmaceuticals (JAZZ), ZEVRA THERAPEUTICS INC (ZVRA), Alnylam Pharmaceuticals (ALNY), COLLEGIUM PHARMACEUTICAL INC (COLL), ADMA BIOLOGICS INC (ADMA), Viking Therapeutics (VKTX), INDIVIOR PHARMACEUTICALS INC (INDV), RHYTHM PHARMACEUTICALS INC (RYTM), ACADIA PHARMACEUTICALS INC (ACAD), ROCKET PHARMACEUTICALS INC (RCKT) and CATALYST PHARMACEUTICALS INC (CPRX). These are ETON PHARMACEUTCIALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ETON competitors & alternatives
-
BioMarin PharmaceuticalBMRNHealth Care
BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene…
$58.40 (as of 2026-07-22) · market cap $11.3B
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
ZEVRA THERAPEUTICS INCZVRAHealth Care
Zevra brings life-changing therapies to ultra-rare neurodegenerative and metabolic diseases, with FDA-approved MIPLYFFA for Niemann-Pick disease type C now…
$12.14 (as of 2026-07-22) · market cap $762M
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
COLLEGIUM PHARMACEUTICAL INCCOLLHealth Care
A specialty pharma company building a diversified pain and ADHD portfolio through branded products and acquisitions, though facing material generic headwinds…
$34.72 (as of 2026-07-22) · market cap $1.1B
-
ADMA BIOLOGICS INCADMAHealth Care
ADMA manufactures and markets FDA-approved plasma-derived immune globulin products for immunodeficient and infectious disease patients, operating an integrated…
$8.38 (as of 2026-07-22) · market cap $2.0B
-
Viking TherapeuticsVKTXHealth Care
Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market…
$37.31 (as of 2026-07-22) · market cap $4.3B
-
INDIVIOR PHARMACEUTICALS INCINDVHealth Care
Indivior is a specialty pharmaceutical company dedicated to developing and marketing treatments for substance use disorders and mental health conditions,…
$40.45 (as of 2026-07-22) · market cap $4.9B
-
RHYTHM PHARMACEUTICALS INCRYTMHealth Care
Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related…
$103.97 (as of 2026-07-22) · market cap $7.1B
-
ACADIA PHARMACEUTICALS INCACADHealth Care
Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare…
$24.96 (as of 2026-07-22) · market cap $4.4B
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
CATALYST PHARMACEUTICALS INCCPRXHealth Care
Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from…
$31.49 (as of 2026-07-21) · market cap $3.9B
Not quite? Describe exactly what you want →
Peers are ETON PHARMACEUTCIALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ETON PHARMACEUTCIALS INC (ETON).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.